Literature DB >> 8172361

Immunoglobulin preparations for intravenous administration. A review of their biologic activities and comparison of various preparation methods.

H Nielsen1.   

Abstract

Substitution therapy with human immunoglobulin preparations is well established in disorders of primary or secondary deficiencies of humoral immunity. However, modifications of the immunoglobulins are required to achieve tolerance for the preferred intravenous route of administration. Several procedures are employed by different commercial suppliers of immunoglobulins, and from the literature it appears that various important biologic functions, e.g., opsonic activity, complement fixation, and Fc-receptor function, are subject to alterations during the preparation. The best preservation of such activity, when assessed in vitro, is obtained with polyethylene glycol precipitation or DEAE-Sephadex fractionation, whereas enzymatic or chemical treatment can potentially reduce the biologic activity. It is recommended that immunoglobulin preparations be evaluated in vitro for intact biologic function before being given to immunodeficient patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8172361     DOI: 10.1111/j.1398-9995.1994.tb00802.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  3 in total

1.  Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations.

Authors:  Malgorzata G Mikolajczyk; Nelydia F Concepcion; Theresa Wang; Douglas Frazier; Basil Golding; Carl E Frasch; Dorothy E Scott
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

2.  Comparative effectiveness of intravenous immunoglobulin for children with Kawasaki disease: a nationwide cohort study.

Authors:  Ming-Chih Lin; Yun-Ching Fu; Sheng-Ling Jan; Mei-Shu Lai
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

3.  Immunomodulatory effects of different intravenous immunoglobulin preparations in chronic lymphocytic leukemia.

Authors:  Ana Colado; Esteban Enrique Elías; Valeria Judith Sarapura Martínez; Gregorio Cordini; Pablo Morande; Fernando Bezares; Mirta Giordano; Romina Gamberale; Mercedes Borge
Journal:  Sci Rep       Date:  2021-06-21       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.